Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

CO2, the Philosopher’s Stone to Obtain Valuable Pharmaceuticals

By Institute of Chemical Research of Catalonia | January 17, 2017

CO2 is used to transform simple molecules into cyclic carbonates, which are then converted into valuable pharmaceuticals. (ICIQ)

Researchers at the Institute of Chemical Research of Catalonia (ICIQ) in Tarragona have developed a method that transforms cyclic carbonates -that can be easily obtained from CO2– into more valuable, chiral molecules chemists call vicinal amino-alcohols. Amino-alcohols are used in a myriad of drugs such as antimalarials, antivirals (like Tamiflu®), analgesics and antiarrhytmics.

The group, led by Prof. Arjan Kleij, develops new methodologies to convert small molecules -like CO2 and other waste gases- into useful chemicals. In previous work, they developed various catalytic routes to functional cyclic carbonates using carbon dioxide and easily accessible chemicals. Kleij and co-workers made these transformations possible with cheap and sustainable iron and aluminium catalysts.

Now, in a new paper recently published in the Journal of the American Chemical Society, ICIQ researchers show how to transform these carbonates into more valuable, highly challenging chiral molecules known as amino-alcohols. The process uses a very efficient palladium catalyst, which is more abundant and less expensive than previously used rhodium alternatives. This reaction also releases CO2, which can be re-used to make new carbonates, thereby closing the cycle.

“Chiral amino-alcohol structures are very common in pharmaceutical products, this new methodology allows us to obtain them selectively from simple, readily available starting materials,” says Aijie Cai, who carried out the experiments. “Moreover, the method is quite user-friendly, it works without any additives or special precautions in just a few hours at 0°C,” he adds.

Prof. Kleij, group leader at ICIQ, comments how “many years ago we developed various efficient ways to prepare functional cyclic carbonates using CO2. Now we are focusing on their post-synthetic conversion to create more challenging molecules with wider application potential. Chiral amino-alcohols are particularly valuable for the pharmaceutical industry, because they are precursors to important drugs such as antivirals and antimalarials.”

CO2 is key to all this process; it is the philosopher’s stone that transforms simple chemicals into valuable drugs. Kleij typically refers to it as “CO2 facilitated chemistry”: without carbon dioxide, none of the reaction steps would work. In the first step, researchers convert the gas into useful cyclic carbonates. During the second step, a palladium-catalysed CO2 elimination triggers the formation of the chiral products. The release of the gas allows the chemistry to move forward. CO2 could be recycled, making the overall process sustainable with minimal carbon emission.

Related Articles Read More >

2025 R&D layoffs tracker tops 92,000
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
DNA microscope offers new 3D view of organisms from the inside out
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE